Lonza Acquires Micronization Firm Micro-MacinazioneBy
Lonza has acquired Micro-Macinazione, a Monteggio, Switzerland-based provider of micronization services, from Cross Equity, a Swiss investment firm.
Micro-Macinazione had 2016 sales of about CHF 20 million ($20.5 million) and has 120 employees.
The acquisition adds to Lonza’s micronization services as part of its drug-product services capabilities, which it gained with the $5.5-billion acquisition of Capsugel, a provider of dosage forms, in July 2017.
The acquisition of Micro-Macinazione builds on Lonza’s/Capsugel’s existing micronization clinical and commercial manufacturing capabilities that are based in Quakertown, Pennsylvania. In January 2016, Capsugel acquired Powdersize, a contract provider of micronization services, and since then, Capsugel has invested in additional capacity at this site that came on stream in early 2017. The Quakertown facility provides particle-size reduction and particle-size control/classification technologies. A focus for the new combined business will be highly potent active pharmaceutical ingredients.